Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is an orally administered, direct-acting, reversible P2Y12 platelet inhibitor. It is a member of the cyclopentyltriazolopyrimidine (CPTP) class.
## Primary Indications
* **Acute Coronary Syndromes (ACS):** Ticagrelor is indicated to reduce the rate of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with ACS or a history of MI.
## Adult Dosing
* **ACS:**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily for at least 12 months.
* **Following ACS:** If ticagrelor is used in ACS patients, a maintenance dose of 60 mg twice daily can be considered for patients older than 40 years who are at high risk for ischemic events but low risk for bleeding, after at least 12 months of treatment with 90 mg twice daily.
* **History of MI:**
* For patients with a history of MI at least 1 year prior, ticagrelor 60 mg twice daily is indicated to reduce the rate of CV death, MI, and stroke.
## Pediatric Dosing
* There is no established pediatric dosing for ticagrelor.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is necessary.
* **Hepatic Impairment:** No dose adjustment is necessary in mild to moderate hepatic impairment. Use with caution in severe hepatic impairment.
## Contraindications
* Active bleeding.
* History of transient ischemic attack (TIA) or stroke.
* Hypersensitivity to ticagrelor or any of its components.
## Adverse Effects
* **Most Common:** Dyspnea, bleeding (including serious and fatal bleeding, primarily gastrointestinal and intracranial), bradycardia, ventricular pauses.
* **Serious:** Life-threatening bleeding, angioedema.
* **Other:** Hypotension, atrial fibrillation, cough, diarrhea, rash.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase ticagrelor concentrations. Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine) may decrease ticagrelor concentrations.
* **CYP3A4 Substrates:** Ticagrelor inhibits CYP3A4 and can increase the concentration of CYP3A4 substrates (e.g., simvastatin, atorvastatin).
* **Aspirin:** Concurrent use with aspirin is recommended for patients with ACS, but higher maintenance doses of aspirin (>100 mg) may decrease the efficacy of ticagrelor.
* **Other Antiplatelets/Anticoagulants:** Increased risk of bleeding. Use with caution.
## Monitoring
* Monitor for signs and symptoms of bleeding.
* Monitor for dyspnea, especially in patients with pre-existing respiratory conditions.
* Assess for drug interactions with concomitant medications.
## Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, meaning its effect is not permanent, unlike clopidogrel.
* Dyspnea is a common side effect and can be dose-limiting for some patients. It is generally not indicative of a serious underlying cardiopulmonary condition but should be evaluated.
* Discontinuation of ticagrelor increases the risk of thrombotic events. If interruption is necessary, consider a transition to another antiplatelet agent.
* Ticagrelor has a faster onset and offset of action compared to clopidogrel.
* The 60 mg twice daily dose is a lower maintenance dose for long-term therapy in specific patient populations.
***
*Always consult the most current prescribing information and relevant clinical guidelines for complete and up-to-date information.*
